BioCentury
ARTICLE | Company News

Chromos, Targeted Genetics deal

June 28, 2004 7:00 AM UTC

CHR will acquire all of the outstanding shares of TGEN's majority-owned subsidiary CellExSys Inc. (Seattle, Wash.) for about C$4.5 million (US$3.3 million). The payment comprises 1.5 million CHR shar...